Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - pemetrexed disodium hemipentahydrate, quantity: 120.82 mg (equivalent: pemetrexed, qty 100 mg) - injection, powder for - excipient ingredients: sodium hydroxide; mannitol; hydrochloric acid - malignant pleural mesothelioma -pemetrexed-aft, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma. non-small cell lung cancer - pemetrexed-aft in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,pemetrexed-aft as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - pemetrexed disodium hemipentahydrate, quantity: 604.12 mg (equivalent: pemetrexed, qty 500 mg) - injection, powder for - excipient ingredients: sodium hydroxide; hydrochloric acid; mannitol - malignant pleural mesothelioma -pemetrexed-aft, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma. non-small cell lung cancer - pemetrexed-aft in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,pemetrexed-aft as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Իսրայել - անգլերեն - Ministry of Health

abic marketing ltd, israel - pemetrexed - powder for concentrate for solution for infusion - pemetrexed 100 mg - pemetrexed - malignant pleural mesothelioma :pemetrexed teva in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. non-small cell lung cancer: pemetrexed teva in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed teva is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. pemetrexed teva is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.

Իսրայել - անգլերեն - Ministry of Health

abic marketing ltd, israel - pemetrexed - powder for concentrate for solution for infusion - pemetrexed 100 mg - pemetrexed - malignant pleural mesothelioma :pemetrexed teva in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. non-small cell lung cancer: pemetrexed teva in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed teva is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. pemetrexed teva is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.

Իսրայել - անգլերեն - Ministry of Health

abic marketing ltd, israel - pemetrexed - powder for concentrate for solution for infusion - pemetrexed 1000 mg - pemetrexed - malignant pleural mesothelioma :pemetrexed teva in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. non-small cell lung cancer: pemetrexed teva in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed teva is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. pemetrexed teva is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.

Իսրայել - անգլերեն - Ministry of Health

abic marketing ltd, israel - pemetrexed - powder for concentrate for solution for infusion - pemetrexed 1000 mg - pemetrexed - malignant pleural mesothelioma :pemetrexed teva in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. non-small cell lung cancer: pemetrexed teva in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed teva is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. pemetrexed teva is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.

Իսրայել - անգլերեն - Ministry of Health

abic marketing ltd, israel - pemetrexed - powder for concentrate for solution for infusion - pemetrexed 500 mg - pemetrexed - malignant pleural mesothelioma :pemetrexed teva in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. non-small cell lung cancer: pemetrexed teva in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed teva is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. pemetrexed teva is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.

Իսրայել - անգլերեն - Ministry of Health

abic marketing ltd, israel - pemetrexed - powder for concentrate for solution for infusion - pemetrexed 500 mg - pemetrexed - malignant pleural mesothelioma :pemetrexed teva in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. non-small cell lung cancer: pemetrexed teva in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed teva is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. pemetrexed teva is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

juno pharmaceuticals nz limited - pemetrexed disodium hemipentahydrate 120.81mg equivalent to pemetrexed 100mg - powder for infusion - 100 mg - active: pemetrexed disodium hemipentahydrate 120.81mg equivalent to pemetrexed 100mg excipient: hydrochloric acid mannitol sodium hydroxide - pemetrexed, in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma.

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

juno pharmaceuticals nz limited - pemetrexed disodium hemipentahydrate 604.05mg equivalent to pemetrexed 500mg - powder for infusion - 500 mg - active: pemetrexed disodium hemipentahydrate 604.05mg equivalent to pemetrexed 500mg excipient: hydrochloric acid mannitol sodium hydroxide - pemetrexed, in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma.